Organic compounds -- part of the class 532-570 series inventions 06/09

20090163716 - Spirocyclic cyclohexane compounds: P

20090163717 - Demethylation of 14-hydroxy substituted alkaloid derivatives: The present invention is directed to a method for demethylating 14-hydroxy substituted alkaloid derivatives, in particular of 14-hydroxy-17-methyl-4,5-epoxymorphinane-6-on-derivatives. This is achieved by reacting a starting compound with a compound of general formula R1OOC—N═N—COOR2 in a suitable solvent.... Agent: The Nath Law Group

20090163718 - Process for the preparation of pyrido[2,1-a] isoquinoline derivatives: wherein R2, R3 and R4 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy and lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by a group consisting of lower alkoxycarbonyl, aryl and heterocyclyl, and the pharmaceutically acceptable... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090163719 - Catalyst compositions and their use in the de-enrichment of enantiomerically enriched substrates: There is provided a process for the de-enrichment of enantiomerically enriched compositions which comprises reacting an enantiomerically enriched composition comprising at least a first enantiomer or diastereomer of a substrate comprising a carbon-heteroatom bond, wherein the carbon is a chiral centre and the heteroatom is a group V heteroatom, in... Agent: Myers Bigel Sibley & Sajovec

20090163720 - Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines: 2-Substituted-5-(1-alkylthio)alkylpyridines are produced efficiently and in high yield from a non-pyridine source by cyclization.... Agent: Dow Agrosciences LLC

20090156814 - Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs: Described herein are opioid prodrugs, methods of making opioid prodrugs, formulations comprising opioid prodrugs, and methods of using opioid prodrugs. One embodiment described herein relates to the transdermal administration of a buprenorphine prodrug in an abuse-resistant formulation for treating and preventing diseases and/or disorders.... Agent: Mayer Brown LLP

20090156815 - N-demethylation of n-methyl morphinans: The present invention provides a synthetic process for the N-demethylation of N-methyl morphinans. In particular, the invention provides improved synthetic methods for the preparation of N-demethylated morphinan compounds that may be employed as starting materials, for example, commonly available N-methyl opiates such as oripavine and thebaine, and C(3)-protected hydroxy derivatives... Agent: Mallinckrodt Inc.

20090156817 - Process for the preparation of buprenorphine and derivatives for buprenorphine: The invention generally provides processes for the production of buprenophine and derivatives of buprenorphine. In particular, the process may encompass synthetic routes for the production of buprenorphine or derivatives of buprenorphine from norhydromorphone or derivatives of norhydromorphone.... Agent: Mallinckrodt Inc.

20090156816 - Sinomenine derivatives and processes for their synthesis: The invention generally provides processes and intermediate compounds useful for the production of sinomenine derivatives. In particular, the process may encompass synthetic routes for the production of (+)-sinomenine derivatives and their intermediates.... Agent: Mallinckrodt Inc.

20090156818 - Process and compounds for the production of (+)opiates: The invention generally provides processes and intermediate compounds useful for the production of (+)-opiates. Non-limiting examples of (+) opiates that may be derived from one or more compounds of the invention include (+)-noroxymorphone, (+)-naltrexone, (+)-naloxone, (+)-N-cyclopropylmethylnorhydrocodone, (+)-N-cycloproylmethylnorhydromorphone, (+)-N-allylnorhydrocodone, (+)-N-allylnorhydromorphone, (+)-noroxycodone, (+)-naltrexol, (+)-naloxol, and (+)-3-O-methyl-naltrexone.... Agent: Mallinckrodt Inc.

20090156819 - Processes for the preparation of normorphinan salts: The invention provides a process for the conversion of opioid derivatives into normorphinan compounds useful for making “nal” compound analgesics and antagonists. In particular, the process may be used for the production of pure normorphinan salts from crude opioid substrates.... Agent: Mallinckrodt Inc.

20090156820 - Processes for the production of (+)- \"nal\" morphinan compounds: The invention generally provides processes and intermediate compounds useful for the production of (+) nal morphinan compounds. In particular, the process encompasses synthetic routes for the production of (+) nal morphinan compounds or derivatives of (+) nal morphinan compounds from (+)-morphinan substrates such as (+)-hydrocodone, (+)-norhydrocodone or derivatives of either... Agent: Mallinckrodt Inc.

20090156821 - Quinazoline compounds: The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is —O—, —NH— or —S—; n is 0-5; m is 0-3; R1 and R2 are defined herein including groups: (i) Q1X1 wherein Q1 and X1 are as... Agent: Morgan Lewis & Bockius LLP

20090156822 - Hepatitis c inhibitor dipeptide analogs: e

20090156823 - Sulfonamide compound and crystal thereof: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which... Agent: Birch Stewart Kolasch & Birch

20090156824 - Hydroamination of alkenes: R1 is an organic group including a sp3 carbon atom bonded to CA. R2 is selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CA. R3 and R4 independently are selected from the group consisting of hydrogen, methyl, and an... Agent: Blanchard & Associates

20090156825 - Fluorescent compounds that bind to histone deacetylase: The present invention relates to a novel class of fluorescent compounds that bind to histone deacetylases. The fluorescent compounds can be used to determine binding association and dissociation rates of histone deacetylase inhibitors via fluorescence polarization.... Agent: Merck And Co., Inc

20090149653 - Transition metal complexes with carbene ligands and their application: The present invention discloses a transition metal complex having carbene ligands. The disclosed transition metal complex has a structure of a center transition metal surrounded by two identical carbene ligands and one double-chilating ligand which is a nitrogen-contain heteroaryl group compound with pyridyl group. The disclosed transition metal complex can... Agent: Wpat, PC

20090149654 - Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes: wherein R1 is a C1-C20 aliphatic, a C2-C20 cycloaliphatic, or a C2-C20 aromatic radical comprising at least one functional group susceptible to reaction with nucleophilic fluoride ion or an electrophilic fluorinating agent; R2 is a C1-C10 aliphatic radical; R3 is hydrogen or a C1-C10 aliphatic radical; R4 is hydrogen or... Agent: General Electric Company Global Research

20090149655 - Process for the preparation of retapamulin and its intermediates: are provided where LG represents a leaving group. The tropine derivatives may be used to prepare Retapamulin, preferably in substantially pure form. Also provided are processes for preparing Retapamulin comprising combining a base, tropine thiol in a free base or salt form, an organic solvent, and a pleuromutilin derivative of... Agent: Kenyon & Kenyon LLP

20090149656 - Optical determination of glucose utilizing boronic acid adducts: The present invention concerns an improved optical method and optical sensing device for determining the levels of polyhydroxyl-substituted organic molecules in vitro and/or in vivo in aqueous media. The range of detection is between about 400 and 800 nm. In particular, a sensory devise is implemented in a mammal to... Agent: Techlaw LLP

20090143584 - Transition metal complexes with (pyridyl)imidazole ligands: Novel transition metal complexes of iron, cobalt, ruthenium, osmium, and vanadium are described. The transition metal complexes can be used as redox mediators in enzyme-based electrochemical sensors. The transition metal complexes include substituted or unsubstituted (pyridyl)imidazole ligands. Transition metal complexes attached to polymeric backbones are also described.... Agent: Bozicevic, Field & Francis LLP

20090143585 - Bifunctional catalysts for extensive isomerization of unsaturated hydrocarbons: The current invention provides novel bifunctional catalysts. The bifunctional catalysts are prepared from phosphine ligands and a cyclopentadienyl metal complex and are useful for forming isomers of hydrocarbon species. The hydrocarbon can be an alkenol having the alkene and alcohol groups far apart and the catalyst will move the double... Agent: Catalyst Law Group, Apc

20090143586 - Method for producing alkyl-substituted aromatic and heteroaromatic compounds by cross-coupling alkyl boronic acids with aryl-or heteroaryl-halogenides or sulfonates under pd catalysis in the presence of a ligand: The invention relates to a method for producing alkyl-substituted aromatic and heteroaromatic compounds by cross-coupling alkyl boronic acids with aryl- or heteroaryl-halogenides or with aryl- or heteroaryl-sulfonates in the presence of a catalyst and of a Brönsted base in a solvent or solvent mixture.... Agent: Propat, L.L.C.

20090143587 - Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes: wherein Q is a carbonyl group, a protected carbonyl group, a hydroxy methine group, or a protected hydroxy methine group; R1 is a C1-C20 aliphatic, C2-C20 cycloaliphatic, or C2-C20 aromatic radical comprising at least one functional group susceptible to reaction with nucleophilic fluoride ion or an electrophilic fluorinating agent; R2... Agent: General Electric Company Global Research

20090143588 - Quartz glass micro-photoreactor and synthesis of 10-hydroxycamptothecin and 7-alkyl 10-hydroxycamptothecin: e

20090143589 - Preparation of dihydropyrrol derivatives as intermediates: The invention is concerned with a new scalable process for the preparation of compounds of formula I comprising a new process for the preparation of the key intermediate, a dihydropyrrole derivative formula II or a salt thereof.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090143590 - Process for the preparation of montelukast and its salts: The present invention relates to an improved process for the preparation of 1-[[[(1R)-1-[3[(1E)-2-(7chloro-2-quinolinyl) ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid (Formula-1) and its salts using Methyl 2-[(3S)-[3-[(2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoate (Formula-2)... Agent: Schweitzer Cornman Gross & Bondell LLP

20090143591 - Scalable synthesis of imidazole derivatives: Imidazole derivatives, compositions containing them, methods of preparing them, including regioselective scale-up synthetic methods, and methods of using them.... Agent: Philip S. Johnson Johnson & Johnson

20090143592 - Glucagon antagonists/inverse agonists: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes,... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090143593 - Synthesis of heterocyclic compounds: Methods for the synthesis of heterocyclic compounds including N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090143594 - Process for the catalytic synthesis of diaryl ethers: t

20090143595 - Use of grinding in chemical synthesis: A process for the preparation of a multi-dimensional microporous metal-organic compound comprising the steps of providing a first reactant which includes at least one metal in ionic form, providing a second reactant which includes a bridging organic ligand, grinding the first and second reactants together, wholly or substantially in the... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group